Masato Kiyoshi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Masato Kiyoshi has a total of 120 co-authors. Here are the top co-authors by number of shared publications:
Akiko Ishii-Watabe
14 shared publicationsHiroko Shibata
Division of Biological Chemistry and Biologicals, National Institute of Health Sciences, Kawasaki, Japan
9 shared publications- Kouhei Tsumoto
Department of Bioengineering, School of Engineering, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8656, Japan
9 shared publications - Jose M. M. Caaveiro
Laboratory of Protein Drug Discovery, Graduate School of Pharmaceutical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Japan
6 shared publications Minoru Tada
Division of Biological Chemistry and Biologicals, National Institute of Health Sciences, Kawasaki, Japan
5 shared publications- Satoru Nagatoishi
The University of Tokyo
5 shared publications
Latest Publications
- Open Access
- 1 September 2026
- Published by Pharmaceutical Society of Japan in YAKUGAKU ZASSHI
- Vol. 146 (9) , 757-763
Elucidation of the Molecular Mechanism Underlying Function of Therapeutic Antibodies and the Development of Quality Assessment Methods
- 1 September 2026
- Published by Pharmaceutical Society of Japan in YAKUGAKU ZASSHI
- Vol. 146 (9) , 757-763
Open AccessElucidation of the Molecular Mechanism Underlying Function of Therapeutic Antibodies and the Development of Quality Assessment Methods
- 18 July 2026
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 831
Position-dependent effects of loop proline residues on Fab stability and aggregation
- 18 July 2026
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 831
Position-dependent effects of loop proline residues on Fab stability and aggregation
- Open Access
- 4 March 2026
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 14 (3) , e013316
Antibody therapeutics with high affinity for FcγRs exacerbate anaphylaxis via FcγR-mediated capture by tumor-associated myeloid cells
Background: Antibody therapeutics have revolutionized cancer treatment, but their use is increasingly associated with adverse events. Among these, anaphylaxis is particularly concerning due to its severity and unpredictability. Our previous studies demonstrated that repeated administration of anti-programmed death-ligand 1 antibodies to tumor-bearing mice induces antidrug antibodies (ADAs) and anaphylaxis. However, the specific characteristics of antibody therapeutics responsible for this effect and the underlying mechanism of ADA production remain poorly understood. This study aimed to identify the immunological and molecular determinants of ADA-associated anaphylaxis following antibody therapeutics in tumor-bearing hosts. Methods: CT26 and 4T1 tumor-bearing mice were repeatedly administered various therapeutic antibodies with differing affinities for Fcγ receptors (FcγRs). Anaphylaxis symptoms, body temperature, and mortality were evaluated. Serum ADA levels were quantified using ELISA. Antibody affinity for mouse FcγR was determined using surface plasmon resonance. Antibody distribution in the spleen was assessed via immunofluorescence staining, and antibody glycosylation was analyzed by liquid chromatography-mass spectrometry. Immune cell populations were examined using flow cytometry. Results: Repeated administration of antibodies with high affinities for FcγRs to tumor-bearing mice induced robust ADA production and anaphylaxis, whereas antibodies with low affinities for FcγRs against the same target elicited only minimal ADA responses and did not trigger anaphylaxis. We identified this difference as being attributed to the ability of tumor-associated monocytic–macrophage lineage cells to capture antibodies via FcγR, altering antibody biodistribution in the spleen, thereby facilitating antigen presentation and activating humoral immunity. Pretreatment with FcγR blocking antibodies attenuated this response, reducing anaphylaxis severity and improving survival. Analysis of clinical therapeutic antibodies also showed that those with a high affinity for FcγRs have a higher risk of inducing anaphylaxis, whereas neutralizing/blocking antibodies with a low or no affinity for FcγRs have a lower risk. Conclusions: High affinities for FcγRs were identified as a critical determinant of anaphylaxis and reveal a mechanism linking FcγR-mediated antibody capture by tumor-associated myeloid cells to ADA induction. This contributes to the mechanistic foundation of AllergoOncology, an emerging interdisciplinary field exploring the interplay between cancer pathology and hypersensitivity reactions to therapeutic agents and providing insights for improving the safety and design of antibody therapeutics.
- 4 March 2026
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 14 (3) , e013316
Open AccessAntibody therapeutics with high affinity for FcγRs exacerbate anaphylaxis via FcγR-mediated capture by tumor-associated myeloid cells
Background: Antibody therapeutics have revolutionized cancer treatment, but their use is increasingly associated with adverse events. Among these, anaphylaxis is particularly concerning due to its severity and unpredictability. Our previous studies demonstrated that repeated administration of anti-programmed death-ligand 1 antibodies to tumor-bearing mice induces antidrug antibodies (ADAs) and anaphylaxis. However, the specific characteristics of antibody therapeutics responsible for this effect and the underlying mechanism of ADA production remain poorly understood. This study aimed to identify the immunological and molecular determinants of ADA-associated anaphylaxis following antibody therapeutics in tumor-bearing hosts. Methods: CT26 and 4T1 tumor-bearing mice were repeatedly administered various therapeutic antibodies with differing affinities for Fcγ receptors (FcγRs). Anaphylaxis symptoms, body temperature, and mortality were evaluated. Serum ADA levels were quantified using ELISA. Antibody affinity for mouse FcγR was determined using surface plasmon resonance. Antibody distribution in the spleen was assessed via immunofluorescence staining, and antibody glycosylation was analyzed by liquid chromatography-mass spectrometry. Immune cell populations were examined using flow cytometry. Results: Repeated administration of antibodies with high affinities for FcγRs to tumor-bearing mice induced robust ADA production and anaphylaxis, whereas antibodies with low affinities for FcγRs against the same target elicited only minimal ADA responses and did not trigger anaphylaxis. We identified this difference as being attributed to the ability of tumor-associated monocytic–macrophage lineage cells to capture antibodies via FcγR, altering antibody biodistribution in the spleen, thereby facilitating antigen presentation and activating humoral immunity. Pretreatment with FcγR blocking antibodies attenuated this response, reducing anaphylaxis severity and improving survival. Analysis of clinical therapeutic antibodies also showed that those with a high affinity for FcγRs have a higher risk of inducing anaphylaxis, whereas neutralizing/blocking antibodies with a low or no affinity for FcγRs have a lower risk. Conclusions: High affinities for FcγRs were identified as a critical determinant of anaphylaxis and reveal a mechanism linking FcγR-mediated antibody capture by tumor-associated myeloid cells to ADA induction. This contributes to the mechanistic foundation of AllergoOncology, an emerging interdisciplinary field exploring the interplay between cancer pathology and hypersensitivity reactions to therapeutic agents and providing insights for improving the safety and design of antibody therapeutics.
- Open Access
- 3 March 2026
- Published by Springer Nature in Communications Biology
- Vol. 9 (1)
Integrative structural insights into the IgG-FcRn interactions revealed by engineered FcRn-immobilized affinity chromatography
Molecular interactions between therapeutic antibodies and neonatal Fc receptor (FcRn) are major contributors to the long serum half-life of antibodies. Therefore, the in vitro affinity of IgG for FcRn is an important indicator of in vivo pharmacokinetic properties. However, the molecular basis of IgG-FcRn interactions is not fully understood from experimental and structural perspectives. Affinity evaluation using surface plasmon resonance is difficult. The molecular mechanism by which domains other than Fc or surface charges affect FcRn binding remains unclear. In this study, we developed an engineered FcRn-immobilized column for affinity chromatography. We analyzed various types of antibodies to link physicochemical characteristics and FcRn affinity. Furthermore, analysis using charge-engineered mutants indicated that the lateral surface of L chain also affects the FcRn affinity. Finally, we presented a structural model of the IgG-FcRn complex to discuss the molecular mechanism of how the charges at L chain affect the FcRn affinity.
- 3 March 2026
- Published by Springer Nature in Communications Biology
- Vol. 9 (1)
Open AccessIntegrative structural insights into the IgG-FcRn interactions revealed by engineered FcRn-immobilized affinity chromatography
Molecular interactions between therapeutic antibodies and neonatal Fc receptor (FcRn) are major contributors to the long serum half-life of antibodies. Therefore, the in vitro affinity of IgG for FcRn is an important indicator of in vivo pharmacokinetic properties. However, the molecular basis of IgG-FcRn interactions is not fully understood from experimental and structural perspectives. Affinity evaluation using surface plasmon resonance is difficult. The molecular mechanism by which domains other than Fc or surface charges affect FcRn binding remains unclear. In this study, we developed an engineered FcRn-immobilized column for affinity chromatography. We analyzed various types of antibodies to link physicochemical characteristics and FcRn affinity. Furthermore, analysis using charge-engineered mutants indicated that the lateral surface of L chain also affects the FcRn affinity. Finally, we presented a structural model of the IgG-FcRn complex to discuss the molecular mechanism of how the charges at L chain affect the FcRn affinity.
- Open Access
- 26 February 2026
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 115 (5) , 104218
Flow imaging for particle characterization and quantification in biologicals: A perspective from the Japanese Biopharmaceutical Consortium
- 26 February 2026
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 115 (5) , 104218
Open AccessFlow imaging for particle characterization and quantification in biologicals: A perspective from the Japanese Biopharmaceutical Consortium
- 5 February 2026
- Published by Oxford University Press (OUP) in The Journal of Biochemistry
- Vol. 179 (5) , 341-349
Chimeric Fab incorporating the IgM Cμ1 domain: insights into physicochemical properties
Fab has been extensively studied to elucidate the structural and physicochemical principles underlying antigen recognition. While most investigations have focused on IgG-derived Fabs, comparatively little is known about those from other isotypes. To investigate the role of the IgM constant domain Cμ1, we engineered a chimeric Fab (Cμ1Fab) in which the CH1 domain of adalimumab Fab (IgG1) was replaced by the human IgM Cμ1 domain. Cμ1Fab was expressed in CHO cells and its physicochemical properties were evaluated. SDS-PAGE analysis with or without PNGase F treatment demonstrated that the N166–N167–S168 motif was N-glycosylated. SPR analysis demonstrated that Cμ1Fab retained antigen-binding activity comparable to that of the wild-type Fab, and elimination of the glycosylation motif (N166A) did not alter binding affinity. Notably, N-linked glycosylation within the Cμ1 domain suppressed aggregation, whereas the N166A variant showed marked aggregation. DSC further revealed that the glycosylation affected thermal stability. The melting temperature (Tm) of the N166A variant was 60.5°C, substantially lower than that of the Cμ1Fab (Tm = 66.0°C), although Tm of the wild-type Fab was 75.2°C. Collectively, these findings establish the critical role of native Cμ1 N-linked glycosylation in Fab stability, offering new insights for antibody engineering.
- 5 February 2026
- Published by Oxford University Press (OUP) in The Journal of Biochemistry
- Vol. 179 (5) , 341-349
Chimeric Fab incorporating the IgM Cμ1 domain: insights into physicochemical properties
Fab has been extensively studied to elucidate the structural and physicochemical principles underlying antigen recognition. While most investigations have focused on IgG-derived Fabs, comparatively little is known about those from other isotypes. To investigate the role of the IgM constant domain Cμ1, we engineered a chimeric Fab (Cμ1Fab) in which the CH1 domain of adalimumab Fab (IgG1) was replaced by the human IgM Cμ1 domain. Cμ1Fab was expressed in CHO cells and its physicochemical properties were evaluated. SDS-PAGE analysis with or without PNGase F treatment demonstrated that the N166–N167–S168 motif was N-glycosylated. SPR analysis demonstrated that Cμ1Fab retained antigen-binding activity comparable to that of the wild-type Fab, and elimination of the glycosylation motif (N166A) did not alter binding affinity. Notably, N-linked glycosylation within the Cμ1 domain suppressed aggregation, whereas the N166A variant showed marked aggregation. DSC further revealed that the glycosylation affected thermal stability. The melting temperature (Tm) of the N166A variant was 60.5°C, substantially lower than that of the Cμ1Fab (Tm = 66.0°C), although Tm of the wild-type Fab was 75.2°C. Collectively, these findings establish the critical role of native Cμ1 N-linked glycosylation in Fab stability, offering new insights for antibody engineering.
- Open Access
- 23 September 2025
- Published by Elsevier in Biochemistry and Biophysics Reports
- Vol. 44, 102269
Characterization of adalimumab Fab variants with the CH1 domain replaced by the Cα1 domain of IgA
- 23 September 2025
- Published by Elsevier in Biochemistry and Biophysics Reports
- Vol. 44, 102269
Open AccessCharacterization of adalimumab Fab variants with the CH1 domain replaced by the Cα1 domain of IgA
- Open Access
- 2 October 2023
- Published by Springer Nature in Scientific Reports
- Vol. 13 (1) , 1-12
Specific peptide conjugation to a therapeutic antibody leads to enhanced therapeutic potency and thermal stability by reduced Fc dynamics
Antibody–drug conjugates are powerful tools for combatting a wide array of cancers. Drug conjugation to a therapeutic antibody often alters molecular characteristics, such as hydrophobicity and effector function, resulting in quality deterioration. To develop a drug conjugation methodology that maintains the molecular characteristics of the antibody, we engineered a specific peptide for conjugation to the Fc region. We used trastuzumab and the chelator (DOTA) as model antibody and payload, respectively. Interestingly, peptide/DOTA-conjugated trastuzumab exhibited enhanced antibody-dependent cellular cytotoxicity (ADCC) and increased thermal stability. Detailed structural and thermodynamic analysis clarified that the conjugated peptide blocks the Fc dynamics like a “wedge.” We revealed that (1) decreased molecular entropy results in enhanced ADCC, and (2) blockade of Fc denaturation results in increased thermal stability. Thus, we believe that our methodology is superior not only for drug conjugation but also as for reinforcing therapeutic antibodies to enhance ADCC and thermal stability.
- 2 October 2023
- Published by Springer Nature in Scientific Reports
- Vol. 13 (1) , 1-12
Open AccessSpecific peptide conjugation to a therapeutic antibody leads to enhanced therapeutic potency and thermal stability by reduced Fc dynamics
Antibody–drug conjugates are powerful tools for combatting a wide array of cancers. Drug conjugation to a therapeutic antibody often alters molecular characteristics, such as hydrophobicity and effector function, resulting in quality deterioration. To develop a drug conjugation methodology that maintains the molecular characteristics of the antibody, we engineered a specific peptide for conjugation to the Fc region. We used trastuzumab and the chelator (DOTA) as model antibody and payload, respectively. Interestingly, peptide/DOTA-conjugated trastuzumab exhibited enhanced antibody-dependent cellular cytotoxicity (ADCC) and increased thermal stability. Detailed structural and thermodynamic analysis clarified that the conjugated peptide blocks the Fc dynamics like a “wedge.” We revealed that (1) decreased molecular entropy results in enhanced ADCC, and (2) blockade of Fc denaturation results in increased thermal stability. Thus, we believe that our methodology is superior not only for drug conjugation but also as for reinforcing therapeutic antibodies to enhance ADCC and thermal stability.
- Open Access
- 1 March 2021
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 110 (3) , 1189-1196
Characterization of Aggregated Antibody-Silicone Oil Complexes: From Perspectives of Morphology, 3D Image, and Fcγ Receptor Activation
- 1 March 2021
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 110 (3) , 1189-1196
Open AccessCharacterization of Aggregated Antibody-Silicone Oil Complexes: From Perspectives of Morphology, 3D Image, and Fcγ Receptor Activation
- 27 October 2020
- Published by Oxford University Press (OUP) in The Journal of Biochemistry
- Vol. 169 (4) , 435-443
Glycosylation decreases aggregation and immunogenicity of adalimumab Fab secreted fromPichia pastoris
Glycoengineering of therapeutic proteins has been applied to improve the clinical efficacy of several therapeutics. Here, we examined the effect of glycosylation on the properties of the Fab of the therapeutic antibody, adalimumab. An N-glycosylation site was introduced at position 178 of the H chain constant region of adalimumab Fab through site-directed mutagenesis (H:L178N Fab), and the H:L178N Fab was produced in Pichia pastoris. Expressed mutant Fab contained long and short glycan chains (L-glyco Fab and S-glyco Fab, respectively). Under the condition of aggregation of Fab upon pH shift-induced stress, both of L-glyco Fab and S-glyco Fab were less prone to aggregation, with L-glyco Fab suppressing aggregation more effectively than the S-glyco Fab. Moreover, the comparison of the antigenicity of glycosylated and wild-type Fabs in mice revealed that glycosylation resulted in the suppression of antigenicity. Analysis of the pharmacokinetic behaviour of the Fab, L-glyco Fab and S-glyco Fab indicated that the half-lives of glycosylated Fabs in the rats were shorter than that of wild-type Fab, with L-glyco Fab having a shorter half-life than S-glyco Fab. Thus, we demonstrated that the glycan chain influences Fab aggregation and immunogenicity, and glycosylation reduces the elimination half-life in vivo.
- 27 October 2020
- Published by Oxford University Press (OUP) in The Journal of Biochemistry
- Vol. 169 (4) , 435-443
Glycosylation decreases aggregation and immunogenicity of adalimumab Fab secreted fromPichia pastoris
Glycoengineering of therapeutic proteins has been applied to improve the clinical efficacy of several therapeutics. Here, we examined the effect of glycosylation on the properties of the Fab of the therapeutic antibody, adalimumab. An N-glycosylation site was introduced at position 178 of the H chain constant region of adalimumab Fab through site-directed mutagenesis (H:L178N Fab), and the H:L178N Fab was produced in Pichia pastoris. Expressed mutant Fab contained long and short glycan chains (L-glyco Fab and S-glyco Fab, respectively). Under the condition of aggregation of Fab upon pH shift-induced stress, both of L-glyco Fab and S-glyco Fab were less prone to aggregation, with L-glyco Fab suppressing aggregation more effectively than the S-glyco Fab. Moreover, the comparison of the antigenicity of glycosylated and wild-type Fabs in mice revealed that glycosylation resulted in the suppression of antigenicity. Analysis of the pharmacokinetic behaviour of the Fab, L-glyco Fab and S-glyco Fab indicated that the half-lives of glycosylated Fabs in the rats were shorter than that of wild-type Fab, with L-glyco Fab having a shorter half-life than S-glyco Fab. Thus, we demonstrated that the glycan chain influences Fab aggregation and immunogenicity, and glycosylation reduces the elimination half-life in vivo.